drugset / Trial / NCT05573126
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Timeline
- Start
- 2023-01-11
- Primary completion
- 2028-02
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EP0062 | Other / unclassified | — | Oral |
| Background | Abemaciclib | Small molecule | — | — |
| Background | Elacestrant | Other / unclassified | — | Oral |
| Background | Everolimus | Small molecule | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | Oral |